Understanding surgical outcomes of perioperative durvalumab in AEGEAN study

Adding perioperative durvalumab to neoadjuvant chemotherapy did not adversely impact surgery in patients with resectable NSCLC and was associated with a tolerable surgical safety profile, according to research presented from the phase 3 AEGEAN trial at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer in Singapore.

With naloxone now more available, HHS officials tout its use

During the same week that naloxone—a nasal spray that reverses opioid overdoses—became available for purchase without a prescription, the nation’s top substance use officials called for greater availability and training for the drug, with five federal officials receiving training to administer it during a public demonstration at Health and Human Services headquarters Friday.

Exercise patience – LGAZ tells Councilors

By Nation Reporter

THE Local Government Association of Zambia (LGAZ) has urged its members to exercise patience as government works on improving their remuneration. 

This content is locked

This is exclusive material. To read full story, click on register and choose one of the premium subscriptions to view this content. Login if you are already a premium user.


Cancer-causing mutations rewire growth signaling in prostate cancer model

Experts in cell signaling at the Babraham Institute have identified how prostate cancer cells achieve cell growth free from the usual growth cues and regulators. This discovery has implications for potential therapeutics in prostate cancer and other cancer types as understanding more about this network remodeling and the drivers of cellular growth provides molecular targets for drugs to stop tumor progression.